The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 23, 2026 for Ravi Agrawal, trustee ....
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Ravi Agrawal, a promoter and trustee of Ajanta Pharma, has disclosed both the creation and release of a pledge on 5,33,333 equity shares (approximately 0.43% of total share capital) on March 17, 2026. The pledge creation was done for re-financing purposes with Bajaj Finance Limited as the lender, while the release was for 'excess pledge'. After these transactions, the total encumbered shares held by the Ravi Agrawal Trust remain unchanged at 60,63,920 shares, representing 4.85% of the company's share capital. The net effect is neutral as an equal number of shares were pledged and released in what appears to be a routine refinancing of existing loans.
This is a neutral event for shareholders since the overall pledged percentage stays the same at 4.85%. The simultaneous creation and release reflects routine loan refinancing rather than any change in the promoter's financial position or stake. No material impact on stock price is expected.